Novel catheter to reduce Urinary Tract Infections (UTIs)

Description du projet

Des sondes urinaires innovantes pour réduire les infections et améliorer la qualité de vie des patients

Les sondes urinaires (SU) sont utilisées lors d’interventions et de traitements médicaux, en cas d’incontinence ou de rétention urinaire dans des situations de lésions de la moelle épinière, d’hypertrophie de la prostate et de nombreuses autres pathologies. Les SU sont synonymes de dégradation de la qualité de vie des patients, de visites fréquentes aux urgences et de risque accru d’infection, tant du point de vue des patients que des professionnels de la santé. Le projet T-CONTROL, financé par l’UE, développe une SU améliorée de conception innovante et dotée d’une membrane hydrophobe spéciale, afin de remédier aux insuffisances des SU actuellement disponibles. Les objectifs du projet sont notamment la validation clinique de la valeur ajoutée, l’enregistrement du produit et son lancement.

Objectif

T-Control is an innovative indwelling urinary catheter. Urinary Catheters (UC) are one of the most frequently used medical devices
on the market. They are used during medical interventions and treatment, as well as incontinence or urine retention in case
of spinal cord injury, prostate hypertrophy, weak muscle, and many other conditions.

There are several unmet needs related to currently used catheters. They cause a sharp decline of quality of life of the
patients, are linked to frequent emergency visits and increase substentially the risk of infection both for patients and health
care professionals. There are about 1,3 million cases in EU, causing 1,8 bn EUR direct cost and more than 14,000 deaths.

T-Control is addressing all the previously mentioned problems thanks to its novel design and a special hydrophobic membrane material, with patent approval both in EU and US, developed after 4 years of R&D.

T-Control will reduce additional days of hospitalization (leading to €1.14B savings in EU alone), but also guarantee the safety of health workers and decreasing continence related waste (sheets, gloves, diapers, catheters, bags…) representing around 29% of medical waste in non-acute hospitals.

Rethink Medical SL develops new medical solutions, mainly linked to nursing. It raised the interest of 16 stakeholders on the market (Letters of Support).

The feasibility study (SME Phase 1) shall address a financial plan, foreseeing all the costs and investments associated with commercializing our custom-made UC and the expected revenues. The study will also aim at assessing other important aspects such as IPR management, determine the best investment route for the growth stage, and conclude the best channels to reach customers and how we can best explain our difference from competition (prescribers, events, hospitals…). All these activities will lead to the ratification of a detailed business plan that will pave the way towards an effective market introduction.

Champ scientifique

Programme(s)

Thème(s)

EIC-SMEInst-2018-2020 - SME instrument

Appel à propositions

H2020-EIC-SMEInst-2018-2020

Voir d’autres projets de cet appel

Sous appel

H2020-SMEInst-2018-2020-1

Régime de financement

SME-1 - SME instrument phase 1

Coordinateur

RETHINK MEDICAL SL

Contribution nette de l'UE

€ 50 000,00

Adresse

C/ PRACTICANTE IGNACIO RODRIGUEZ S/N - EDIFICIO PO II DEL CAMPUS UNIVERSITARIO DE TAFIRA
35017 LAS PALMAS DE GRAN CANARIA
Espagne

PME

Oui

Région

Canarias Canarias Gran Canaria

Type d’activité

Private for-profit entities (excluding Higher or Secondary Education Establishments)

Liens

Contacter l’organisation

Participation aux programmes de R&I de l'UE

Réseau de collaboration HORIZON

Coût total

€ 71 429,00